21.218 articles found

Effect of 650 nm laser photobiomodulation therapy on the HT-7 (shenmen) acupoint in the Mus musculus model of Parkinson's disease

Suhariningsih S, Astuti SD, Kusumawati HN, Mahmud AF, Septriana M, Rozykulyyeva L, Susilo Y, Syahrom A.

Heliyon · 2023-04-01

Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson's disease.

Bohnen NI, Yarnall AJ.

Neural Regen Res · 2023-04-01

DOI: 10.4103/1673-5374.353490PMID: 36204846

Correction to: Off-time Treatment Options for Parkinson's Disease.

Fabbri M, Barbosa R, Rascol O.

Neurol Ther · 2023-04-01

DOI: 10.1007/s40120-023-00441-4PMID: 36729359

CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.

Shammas MK, Huang TH, Narendra DP.

Biochem Soc Trans · 2023-04-01

DOI: 10.1042/bst20221365PMID: 37021679

New-onset impulse control disorders after treatment with levodopa-carbidopa intestinal gel in Parkinson's disease.

Contreras Chicote A, Velilla Alonso G, Mas Serrano M, Grandas Perez F.

Neurologia (Engl Ed) · 2023-04-01

DOI: 10.1016/j.nrleng.2022.04.002PMID: 37059573

Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".

Yang X, Xiao Q.

Mov Disord · 2023-04-01

DOI: 10.1002/mds.29368PMID: 37061883

Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.

Müller T, Kuhn W.

Mov Disord · 2023-04-01

DOI: 10.1002/mds.29365PMID: 37061885

Toll-like receptors in pathogenesis of neurodegenerative diseases and their therapeutic potential.

Dabi YT, Ajagbe AO, Degechisa ST.

Immun Inflamm Dis · 2023-04-01

DOI: 10.1002/iid3.839PMID: 37102648

5-HT_1A agonists for levodopa-induced dyskinesia in Parkinson's disease.

Al-Kassmy J, Sun C, Huot P.

Neurodegener Dis Manag · 2023-04-01

DOI: 10.2217/nmt-2022-0039PMID: 37140165

Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer's and Parkinson's diseases.

Tripathi R, Kumar P.

Integr Biol (Camb) · 2023-04-01

DOI: 10.1093/intbio/zyad012PMID: 37635325

Metabolic syndrome as a risk for Parkinson's disease: A new therapeutic opportunity.

Bregonzio C.

Brain Behav Immun · 2023-04-01

DOI: 10.1016/j.bbi.2023.03.030PMID: 37011866

Small‑molecule PKR‑like endoplasmic reticulum kinase inhibitors as a novel targeted therapy for Parkinson's disease.

Lusa W, Rozpędek-Kamińska W, Siwecka N, Galita G, Majsterek I, Kucharska E.

Mol Med Rep · 2023-03-31

DOI: 10.3892/mmr.2023.12989PMID: 36999601